Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2024 Nov;38(16):3125-3131.
doi: 10.1038/s41433-024-03240-9. Epub 2024 Jul 17.

LeptoVitelliform Maculopathy: delineating a distinct clinical entity from acquired vitelliform lesions

Affiliations
Observational Study

LeptoVitelliform Maculopathy: delineating a distinct clinical entity from acquired vitelliform lesions

Serena Fragiotta et al. Eye (Lond). 2024 Nov.

Abstract

Objectives: To characterize acquired vitelliform lesions associated with leptochoroid (i.e., diffuse choroidal thinning) and reticular pseudodrusen (RPD) and compare this phenotype to the acquired vitelliform lesion (AVL) in the dystrophic spectrum.

Methods: This retrospective, observational case-control study enrolled 56 patients (56 eyes) affected by vitelliform lesions (AVL), including 27 patients with AVL associated with RPD and leptochoroid (i.e., choroidal thinning) referred to as LeptoVitelliform Maculopathy (LVM), and 29 AVL patients without other funduscopic abnormalities. The main structural features analysed were the integrity of the external limiting membrane (ELM), ellipsoid zone (EZ), and retinal pigment epithelium (RPE), the presence of hyporeflective spaces, and hypertransmission. Choroidal vascular index (CVI) was calculated using ImageJ software.

Results: Patients with LVM were 6.69 years older and presented smaller vitelliform lesions considering both vertical (P < 0.001) and horizontal diameters (P < 0.001) with a similar visual impairment compared to the AVL group (P = 0.27). The LVM subgroup showed a greater alteration of the ELM (p < 0.001) and choroidal hypertransmission (i = 0.007), accompanied by less frequent RPE bumps (P = 0.001) and hyporeflective spaces within the vitelliform material (P = 0.002). Furthermore, the LVM group presented a lower CVI with a significant attenuation on both the luminal and stromal compartments compared to AVL (P < 0.001, both).

Conclusions: The phenotypic combination of subretinal vitelliform lesion and RPD may delineate a distinct phenotype that shares with AVL only the presence of vitelliform material and a similar visual deterioration. The presented findings of LVM highlight significant structural and microvascular alterations that may hold prognostic relevance, warranting future longitudinal studies.

PubMed Disclaimer

Conflict of interest statement

The authors have no proprietary/financial interest regarding the publication of this study. M. Parravano reports personal fees from Allergan, Novartis, Bayer, Zeiss, Omikron, Alfaintes, Sifi outside the submitted work. R. Sacconi reported personal fees from: Novartis, Bayer, Zeiss outside the submitted work. V. Capuano is consultant for ZEISS (Dublin, USA). G. Querques: Alimera Sciences, Inc.: Consultant/Advisor; Allegro: Advisor; Allergan: Consultant/Advisor; Apellis : Consultant/Advisor; Baush & Lomb: Consultant; Bayer Healthcare Pharmaceuticals: Consultant/Advisor; Boehringer Ingelheim: Advisor; CenterVue: Consultant/Advisor; Heidelberg Engineering: Consultant/Advisor; Lumithera: Advisor; Nevacar: Advisor; Novartis Pharmaceuticals Corporation: Consultant/Advisor; Roche: Consultant/Advisor SIFI: Advisor/Consultant; Sooft/Fidia: Consultant; Topcon: Consultant; Thea: Consultant; Zeiss: Consultant/Advisor. E. H. Souied-consultant for Allergan, Bayer, Novartis, and Roche. F. Bandello -Consultant: Alcon, Alimera Sciences, Allergan, Farmila Théa, Bayer Schering Pharma, Bausch + Lomb, Genentech, Hoffmann-La Roche, Novagali Pharma, Novartis, Sanofi-Aventis, ThromboGenics, Zeiss. The remaining authors have nothing to disclose.

References

    1. Freund KB, Laud K, Lima LH, Spaide RF, Zweifel S, Yannuzzi LA. Acquired Vitelliform Lesions: correlation of clinical findings and multiple imaging analyses. Retina. 2011;31:13–25. - PubMed
    1. Querques G, Forte R, Querques L, Massamba N, Souied EH. Natural course of adult-onset foveomacular vitelliform dystrophy: a spectral-domain optical coherence tomography analysis. Am J Ophthalmol. 2011;152:304–13. - PubMed
    1. Balaratnasingam C, Cherepanoff S, Dolz-Marco R, Killingsworth M, Chen FK, Mendis R, et al. Cuticular Drusen: Clinical Phenotypes and Natural History Defined Using Multimodal Imaging. Ophthalmology. 2018;125:100–18. - PubMed
    1. Lima LH, Laud K, Freund KB, Yannuzzi LA, Spaide RF. Acquired vitelliform lesion associated with large drusen. Retina. 2012;32:647–51. - PubMed
    1. Govetto A, Bhavsar KV, Virgili G, Gerber MJ, Freund KB, Curcio CA, et al. Tractional Abnormalities of the Central Foveal Bouquet in Epiretinal Membranes: Clinical Spectrum and Pathophysiological Perspectives. Am J Ophthalmol. 2017;184:167–80. - PubMed

Publication types

LinkOut - more resources